Regulatory & Legal

Profitable and with little debt, this holding company is leveraging a diverse portfolio as it prepares for a major stock market uplist. Here's a closer look.

With a new regulatory chief, Ray Therapeutics accelerates its mission to bring its goggle-free optogenetic therapies for blindness through clinical trials.

Prestigious toxicology awards recognize UL Research Institutes' vital work on vaping health risks and innovative methods for assessing chemical safety.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

With 23,000 metres of drilling, Copper Giant aims to unlock one of the world's largest undeveloped copper caches, vital for the energy transition.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

A fatal crash and a spike in deaths have prompted a stark warning: the mix of jets, helicopters, and drones in our airspace is a growing global threat.

India's car-sharing leader posts a record quarter, slashing losses by 91% without marketing spend, and now eyes a US market uplisting and new capital.

Ascend Elements' award to TDK Ventures reveals a new VC model, where hands-on partnership is key to building a secure, circular battery supply chain.

Fresh off a $1.1B IPO and a #1 GreenTech ranking, BETA Technologies faces investors to prove its electric aviation vision is commercially viable.

Real estate giant Kennedy Wilson agrees to an all-cash acquisition by its CEO and Fairfax Financial, offering a 46% premium to go private.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

Warner Bros. Discovery pushes for a Netflix merger but opens a one-week window for Paramount Skydance to fix its flawed bid. A bidding war looms.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

New Commerce Dept. duties on Chinese graphite aim to reshape the U.S. battery industry, but will it secure the supply chain or just raise EV costs?

A second real-world study finds an FDA-approved device brings significant relief to over 80% of tinnitus patients, offering new hope for millions.

The fintech giants are launching integrated expense cards with cashback rewards, aiming to turn business spending into a source of savings for European CFOs.

Salmon giant SalMar secures a new 10-year green bond, signaling strong investor confidence in its sustainable strategy despite a negative credit outlook.